The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 869 Weight Management articles
GLP-1 injections like Ozempic, Wegovy, and Mounjaro have exploded from niche diabetes therapies to cultural icons in weight management. While offering profound metabolic benefits, their rapid mainstreaming raises questions about proper use, side effects, and societal pressures. This guide unpacks the science, real-world stories, and future implications.
GLP-1 medications like Zepbound have transformed lives, helping patients lose significant weight amid personal challenges. But rapid results come with risks like gallstones and muscle loss. This guide blends real stories with clinical insights for informed decisions.
Ozempic and Wegovy have transformed weight management, but high costs limit access. A Spanish company is now manufacturing generic semaglutide, poised to slash prices as patents expire. This guide explores the implications for patients seeking affordable GLP-1 therapy.
Demand for GLP-1 weight loss medications is soaring, but the shift to easier-to-fake oral pills spells trouble. Counterfeit versions pose serious health risks, from incorrect dosing to contamination. This guide explains the threats and equips you with strategies to stay safe.
Scotland's NHS spending on GLP-1 weight-loss injections like Mounjaro has skyrocketed to nearly £3 million monthly, fueled by surging prescriptions and a sudden Mounjaro price hike tied to US policy. These drugs offer profound benefits beyond weight loss, reducing risks of heart disease and more. Here's what patients need to know about access, costs, and real-world impact.
Novo Nordisk has redefined obesity and diabetes care with its GLP-1 powerhouse: semaglutide brands Ozempic, Wegovy, and Rybelsus. These injectables and oral options deliver substantial weight loss, glycemic control, and cardiovascular protection. Discover how they work, compare to competitors, and optimize your treatment.
The race for oral GLP-1 medications is intensifying, with Novo Nordisk's oral Wegovy now approved and Eli Lilly's orforglipron facing a brief FDA review extension. These pill-based alternatives to injections promise easier access for weight loss and metabolic health. Learn how they stack up in efficacy, tolerability, and real-world impact.
Generic versions of blockbuster GLP-1 drugs Ozempic and Wegovy are now approved in India, promising lower costs and wider access. Patients can expect semaglutide generics from Sun Pharma, Zydus Lifesciences, and others amid patent expiry in 2026. This guide breaks down the science, benefits, and key considerations for safe use.
A 54-year-old father walked away from his $997 Ozempic prescription due to sky-high costs. GLP-1 medications like Ozempic and Mounjaro offer transformative benefits for diabetes and obesity, yet US prices make them unaffordable for millions. This guide breaks down the pricing crisis, clinical value, and paths to reform.
